Results 101 to 110 of about 6,146 (182)

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless ...
Xinyu Hu, Dan Li, Weijie Chen, Hongyu Kuang, Dan Yang, Zhiyan Gong, Yuxiang Long, Guangliang Liu, Kai Wang, Mengshi Xia, Yanping Xu, Yuehui Yin   +11 more
doaj   +1 more source

A Network Meta-Analysis of the Efficacy and Safety of Empagliflozin at Different Doses in Patients with Diabetes Mellitus Based on Randomized Controlled Trials [PDF]

, 2020
Qian Wu, Chen Di Liao, Mengyu He, Can Li, Fang Zou, Lei Hu, Yiping Wei, Wenxiong Zhang   +7 more
openalex   +1 more source

Empagliflozin attenuates arrhythmogenesis via inhibition of O-GlcNAcylation in diastolic phase of diabetic cardiomyopathy [PDF]

, 2022
Takahide Kadosaka, M. Watanabe, Hiroyuki Natsui, Takuya Koizumi, Taro Koya, Motoki Nakao, Hikaru Hagiwara, Rui Kamada, Taro Temma, Toshihisa Anzai   +9 more
openalex   +1 more source

Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
A 23‐year‐old male with cystic fibrosis developed Takotsubo cardiomyopathy with left ventricular reduced ejection fraction during bilateral lung transplantation. One year later, he presented with reduced left ventricular ejection fraction and pulmonary edema in the context of medication non‐adherence.
Azadeh Moradkhani, Masoume Avateffazeli, Farah Naghashzadeh, Salman Soleimani, Zargham Hossein Ahmadi, Alireza Jahangiri Fard, Sina Homaee, Mohammad Varahram, Mahshid Hajiali, Shadi Shafaghi, Atefeh Abedini   +10 more
wiley   +1 more source

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial

BMC Research Notes
Objective To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM). Results The significant changes in FBS from baseline to week 12 were − 23.
Naimeh Mesri Alamdari, Maryam Barghaman, Neda Roshanravan, Majid Mobasseri, Helda Tutunchi, Amir Baharami, Akbar Aliasgarzadeh, Vahideh Sadra   +7 more
doaj   +1 more source

Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes

, 2022
S. Kahl, Anne Pernille Ofstad, Bernard Zinman, Christoph Wanner, Elke Schüler, Naveed Sattar, Silvio E. Inzucchi, Michael Roden   +7 more
openalex   +1 more source

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Maliha Malik, Hammad Amjad, Khadija Malik, Muddassir Syed Saleem, Shanzay Akhtar, Muslehuddin Paracha, Mobeen Abid, Nabahat Shafi, Ahmed Asad Raza, Abedin Samadi, Samar Abbas Jaffri   +10 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

MedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang, Aimin Jiang, Bin‐Kui Jia, Yuming Jin, Yinghu Chen, Zhaoyu Li, Yan Liao, Haoling Zhang, Zhiheng Lin, Xiao Fang, Linhui Wang   +10 more
wiley   +1 more source

Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort

Diabetic Medicine, Volume 43, Issue 2, February 2026.
Abstract Aims This study assesses national trends and, socio‐demographic and clinical factors associated with polypharmacy and potentially in appropriate prescribing among people with type 2 diabetes in Scotland from 2012 to 2022. Methods Retrospective cohort study using nationwide data from the Scottish Care Information – Diabetes database ...
William Berthon, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Amanda de Assuncao Santiago Fernandes, Lauren E. Walker, Rory J. McCrimmon, Helen M. Colhoun, David A. McAllister, Peter Hanlon   +8 more
wiley   +1 more source

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 935-945, February 2026.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source